Skip to main content
. 2021 Sep 10;88(6):973–983. doi: 10.1007/s00280-021-04351-w

Fig. 2.

Fig. 2

Mean trough serum concentrations of Ruxolitinib of patients receiving 10 mg twice daily in patients without AE-related dose reduction (n = 18) compared to patients with AE-related dose reduction (n = 4) before and after reduction. AE adverse event